Clinical Report: Drug-Resistant Persister Cells in Lymphoid Cancers

Background

Lymphoid malignancies pose significant treatment challenges due to the high rates of therapy resistance and relapse. The cancer stem cell (CSC) hypothesis has traditionally explained some aspects of this resistance, but recent research emphasizes the role of DTP cells as a critical factor in treatment failure.

Data Highlights

No numerical data or trial data provided in the source material.

Key Findings

• DTP cells arise in response to chemotherapy and adopt a quiescent state to survive drug exposure.
• These cells are linked to minimal residual disease (MRD) and can regain proliferative capacity after drug withdrawal.
• DTEP cells may evolve from DTP cells through genomic alterations, stabilizing resistance.
• Resistance mechanisms in DTP cells are primarily driven by non-genetic adaptations.
• Potential therapeutic strategies include targeting glycosylation-related pathways and exploiting immunotherapeutic glycopeptide targets.

Clinical Implications

A deeper understanding of DTP cells may inform the development of treatment strategies aimed at overcoming therapy resistance in lymphoid malignancies.

Conclusion

The exploration of DTP cells in lymphoid cancers provides insights into therapy resistance mechanisms.

Related Resources & Content

1. Frontiers in Oncology, 2026 -- Drug-tolerant persister cells in cancer: a scoping review of definitions, models, and molecular mechanisms
2. Frontiers in Immunology, 2026 -- Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies
3. The ASCO Post, 2025 -- New Treatment Approach Could Enhance Care for Aggressive Relapsed/Refractory T- and NK-Cell Lymphomas
4. Frontiers in Immunology, 2026 -- Mechanisms of first-line treatment resistance in diffuse large B-cell lymphoma
5. 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia
6. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 - PubMed
7. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
8. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) | Journal of Clinical Oncology
9. An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis - PubMed
10. A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas | Oncology and Therapy | Springer Nature Link
11. Frontiers | Drug-tolerant persister cells: the deadly survivors in hematological malignancies
12. Frontiers | Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies
13. 2025 British Society for Haematology Guideline for the treatment of chronic lymphocytic leukaemia
14. NCCN Guidelines® Insights: B-Cell Lymphomas 3.2025 - PubMed
15. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up - PubMed
16. Phase III Trial of Pirtobrutinib Versus Idelalisib/Rituximab or Bendamustine/Rituximab in Covalent Bruton Tyrosine Kinase Inhibitor–Pretreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN CLL-321) | Journal of Clinical Oncology
17. An indirect comparison of pirtobrutinib with second-generation covalent Bruton tyrosine kinase inhibitors in BTKi naive, and relapsed-refractory chronic lymphocytic leukemia: results of a network meta-analysis - PubMed
18. A Meta-analysis Investigating Response Rates with Continuous Bruton Tyrosine Kinase Inhibitor Monotherapies in the Treatment of B Cell Lymphomas | Oncology and Therapy | Springer Nature Link
19. Frontiers | Drug-tolerant persister cells: the deadly survivors in hematological malignancies
20. Frontiers | Resistance mechanisms and overcoming strategies for CAR T-cell therapy in B-cell hematologic malignancies